

Burkholderia cepacia 2

. . . . *

= Abstract =

Two Case of *Burkholderia cepacia* Sepsis

Seong Shik Park, M.D., Sung Ryon Ahn, M.D., Su Eun Park, M.D.
Young Tak Lim, M.D. and Chul Hun L. Chang, M.D.*

Department of Pediatrics and Clinical Pathology, College of Medicine,
Pusan National University, Pusan, Korea*

Burkholderia cepacia, a widespread gram-negative environmental bacillus associated with nosocomial infection, is considered to be of relatively low virulence and rarely to cause invasive disease in immunocompromised patients. Nosocomial infections resulting from the use of contaminated medication, antiseptics and instruments have also been reported in otherwise healthy hosts. We experienced two cases of *B. cepacia* sepsis in 10 year-old male who was medicated with the anticancer drugs for the treatment of acute lymphoblastic leukemia(ALL) and in 15 day-old newborn who was examined with voiding vesicourethrography(VCUG) for the evaluation of congenital hydronephrosis. The organism isolated from serial blood culture in ALL patient and from serial blood culture and urine culture in newborn examined with VCUG. The former ALL patient improved after antibacterial medication of imipenem and the latter newborn improved after treatment with imipenem and trimethoprim-sulfamethoxazole.

Key Words : *Burkholderia cepacia*, Sepsis

5 8)

2, 9 11). *B. cepacia*

Burkholderia cepacia

Pseudomonadaceae Pseudomonas

1, 2)

B. cepacia

가

10, 11)

2 4),

(acute lymphoblastic leukemia; ALL)

가

10

:
Tel : 05 1)240-7298 Fax : 05 1)248-6205
E-mail : naviwith@hanmail.net

(voiding vesicourethrography; VCUG)
B. cepacia

242 : 8 2 2001

Na 140 mEq/L, K 4.2 mEq/L, Cl 99 mEq/L, AST/ALT 119/284 IU/L 가 , (BUN) creatinine 13 mg/dL 0.5 mg/dL . 1.47 mg/dL 가 0.6 mg/dL . C- 0.17 mg/dL 5 5.7 mg/dL 가 . 4

1 : , 10 , : : 11

*B. cepacia*가 carumonam, ciprofloxacin, imipenem, piperacillin, trimethoprim-sulfamethoxazole(TMP-SMX)

Pseudomonas aeruginosa

: *B. cepacia* imipenem cefepime

3 39.4 flucloxacillin isepamicin . 2

Imipenem 24 8 10.8 mg/dL(7.93 mg/dL) AST/ALT

2 isepamicin cefepime 2 3 flucloxacillin vancomycin 2

2 : , 15 , : : 가

4 가 : : 4 100/60 mmHg, 102 / , 24 / 38.1

가 가 3 8 1

가 : 800/mm³(44.9%, 48.8 %), 6.6 g/dL, 26,000/mm³

cefotaxime 10 ampicillin 가 : 38 1 , 3,400 g

Apgar 1 6, 5 8 .
 가 : .
 :
 , 156
 / , 44 / , 38.6
 :
 8,230/mm³ (59%, 23%),
 18.3 g/dL, 140,000/mm³
 Na 144 mEq/L, K 5.0 mEq/L, Cl 105
 mEq/L . AST/ALT 47/10 IU/L
 creatinine 23 mg/dL 0.6 mg/dL
 . 15.0 mg/dL 가
 1.3 mg/dL
 17.3 (INR 1.58), 55.8 C- 8.81
 mg/dL 가
 11 15/HPF, many/HPF, bacteria 2 +
 .
 6,000/mm³, 13.0 g/dL, 3,000/
 mm³ .
B. cepacia 가
 imipenem
 TMP-SMX
 : 7
 ,
 III
 imipenem
 TMP-SMX
B. cepacia 가 ,
 TMP-SMX 가 .
 (paucity of bile duct
 syndrome) .

Burkholderia cepacia 1950 Burkholder
¹⁾
Pseudomonadaceae Pseudomonas
Pseudomonas cepacia, *P. multivorans*, *P. kingii*, Eu-
 gonid oxidizer-group I ^{12, 13)} .
 (glucose nonfermen-
 tative gram-negative bacilli; GNFB)
 가 ²⁾ .
 , ⁹⁾ ,
 가 ¹⁴⁾ . *B. cepacia*
 glucose, maltose, lactose, mannitol, sucrose, xy-
 lose ¹³⁾ .
 가 oxidase polymyxin B
¹⁵⁾ . Penicillin
 G ¹⁶⁾ . *B.*
cepacia
 -lactam aminoglyco-
 sides, polymyxins, carboxypenicillin
 . ureidopenicillin, 3
 cephalosporins, ciprofloxacin, TMP-SMX, monocyc-
 line chloramphenicol ,
 , piper-
 cillin ceftazidime 가
¹⁷⁾ . *B. cepacia* imipenem 6%, amikacin 9%
 가 가 ¹⁸⁾ ,
 meropenem imipenem
¹⁹⁾ .
B. cepacia
 ,
 (chlorhexidine, povidone-iodone, benzalconium
 chloride), , ,
²⁰⁾ .
B. cepacia 가 10⁸ cfu/mL

benzalconium chloride
B. cepacia
 , 1995 ²⁵⁾ ,
 20
 3 *B. cepacia*가

, VCUG
 ALL CVC가
 , 4 CVC
*B. cepacia*가 *B. cepacia*
 ALL (central venous
 catheter; CVC)
 VCUG
 CVC *B. cepacia*가 가
B. cepacia 1988 Rutala ²¹⁾
B. cepacia 2
 , 1993 Pegues ⁵⁾ 14
 heparin flushing
B. cepacia
 CVC 6 CVC
 5 *B. cepacia*
 가 . 1997 Lu ²²⁾ *B. cepacia*
 70 11 ²⁶⁾
 , 1999 Yu ²³⁾ *B. cepacia* Bhagat ²⁷⁾
 25 18 CVC가 *B. cepacia* 73
 11 CVC .
 ceftazidime 92%, piperacillin 89%, mezlo-
 cillin 85%, ciprofloxacin 40% ,
 Gold ¹⁷⁾ ceftazidime
 piperacillin . Saiman ²⁶⁾
 가
 2 . *B. cepacia* 330
 1995 Kahyaoglu ²⁴⁾ *B. cepacia* 652
 CVC,
 2
B. cepacia .
 chloramphenicol/minocycline
 49%, ceftazidime/chloramphenicol 26
 1986 ¹⁰⁾ chlorhexine % , piperacillin/ciprofloxacin 16%, ceftazidime/
B. cepacia 가 1998 ¹¹⁾ TMP-SMX 13%, impenem/tobramycin 7%가

57%

ALL
 carumonam, ciprofloxacin, imipenem, piperacillin, TMP-SMX CVC
 imipenem
 imipenem
 TMP-SMX imipenem
 TMP-SMX
B. cepacia 7† , 2
 TMP-SMX 7†
 10
Burkholderia cepacia

- 1) Burkholder WH. Sour skin, a bacterial rot of onion bulbs. *Phytopathology* 1950;40:115-7.
- 2) LiPuma JJ. *Burkholderia cepacia* epidemiology and pathogenesis : implication for infection control. *Curr Opin Pulm Med* 1998;4:337-41.
- 3) Berry MD, Asmar BI. *Pseudomonas cepacia* bacteremia in children with sickle cell hemoglobinopathies. *Pediatr Infect Dis J* 1991;10:696-9.
- 4) Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, et al. *Pseudomonas cepacia* infection in cystic fibrosis : an emerging problem. *J Pediatr* 1984;104:206-10.
- 5) Pegues DA, Carson LA, Anderson RL, Norgard MJ, Argent TA, Jarvis WR, et al. Outbreak of *Pseudomonas cepacia* bacteremia in oncology patients. *Clin Infect Dis* 1993;16:407-11.
- 6) Keizur JJ, Larin B, Leidich RB. Iatrogenic urinary tract infection with *Pseudomonas cepacia* after transrectal ultrasound guided needle biopsy of the prostate. *J Urol* 1993;149:523-6.
- 7) Lee S, Shiomi M, Ito N, Togawa M, Maeyama M, Yabiku M, et al. An outbreak of *Pseudomonas sepsis* associated with nosocomial infection in pediatric ward. *Kansenshogaku Zasshi* 1993;67:361-5.
- 8) Holmes A, Nolan R, Taylor R, Finley R, Reley M, Jiang R, et al. An endemic of *Burkholderia cepacia* transmitted between patients with and without cystic fibrosis. *J Infect Dis* 1999;179:1197-205.
- 9) Geftic SG, Heymann H, Adair FW. Fourteen-year survival of *Pseudomonas cepacia* in a salts solution preserved with benzalconium chloride. *Appl Environ Microbiol* 1979;37:507-10.
- 10) Chlorhexine *Pseudomonas cepacia* 7† . 1986;18:25-9.
- 11) Benzalconium chloride *Burkholderia cepacia* . 1998;30:545-51.
- 12) Craven DE, Moody B, Connolly MG, Kollisch NR, Stottmeier KD, McCabe WR. Pseudobacteremia caused by povidone-iodine solution contaminated with *Pseudomonas cepacia*. *N Engl J Med* 1981;305:621-3.
- 13) Fang FC, Madinger NE. Resistant nosocomial gram negative bacillary pathogen : *Acinetobacter baumannii*, *Xanthomonas maltophilia* and *Pseudomonas cepacia*. *Curr Clin Top Infect Dis* 1996;16:52-83.
- 14) Drabick JA, Gracey EJ, Heidecker GJ, LiPuma JJ. Survival of *Burkholderia cepacia* on environmental surface. *J Hosp Infect* 1996;32:267-76.
- 15) Richards RM, Richard JM. *Pseudomonas cepacia*

- cia* resistance to antibacterials. *J Pharm Sci* 1979;68:1436-8.
- 16) Beckman W, Lessie TG. Response of *Pseudomonas cepacia* to β -lactam antibiotics: utilization of penicillin G as the carbon source. *J Bacteriol* 1979;140:1136-8.
 - 17) Gold R, Jin E, Levinson H. Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by *Pseudomonas cepacia*. *J Antimicrob Chemother* 1983;12(Suppl A):331-6.
 - 18) Tokars JI, Paul SM, Crane GL, Cetron MS, Finelli L, Jarvis WR. Secular trends in blood stream infection due to antimicrobial-resistant bacteria in New Jersey hospital, 1991-1995. *Am J Infect Control* 1997;25:395-400.
 - 19) Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. *Scand J Infect Dis Suppl* 1995;96:5-10.
 - 20) Brauner A, Hfiby N, Kjartansson J. *Pseudomonas cepacia* septicemia in patients with burns: report of two cases. *Scand J Infect Dis* 1985;17:63-6.
 - 21) Rutala WA, Weber DJ, Thomann CA, John JF, Saviteer SM, Sarubbi FA. An outbreak of *Pseudomonas cepacia* bacteremia associated with a contaminated intra-aortic balloon pump. *J Thoracic Cardiovasc Surg* 1988;16:407-11.
 - 22) Lu DCT, Chang SC, Chen YC, Luh KT, Lee CY, Hsieh WC. *Burkholderia cepacia* bacteremia: a retrospective analysis of 70 episodes. *J Formos Med Assoc* 1997;96:972-8.
 - 23) Yu WL, Wang DY, Lin CW, Tsou MF. Endemic *Burkholderia cepacia* bacteremia: Clinical features and antimicrobial susceptibilities of isolates. *Scand J Infect Dis* 1999;31:293-8.
 - 24) Kahyaoglu O, Nolan B, Kumar A. *Burkholderia cepacia* sepsis in neonates. *Pediatr Infect Dis J* 1995;14:815-6.
 - 25)
. *Pseudomonas cepacia*
1 . 1995;14:405-9.
 - 26) Burns JL, Saiman L. *Burkholderia cepacia* infection in cystic fibrosis. *Pediatr Infect Dis J* 1999;18:155-6.
 - 27) Bhakta DR, Learder I, Jacobson R, Robinson-Dunn B, Honicky RE, Kumar A. Antibacterial properties of investigational, new, and commonly used antibiotics against isolates of *Pseudomonas cepacia*. *FEMS Microbiol Lett* 1994;122:251-6.